Patents Examined by Heidi L Reese
  • Process for the preparation of [[2(S)-[[4(R)-(3-hydroxyphenyl)-3(R),4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]amino]acetic acid dihydrate
    Patent number: 10093625
    Abstract: The present invention relates to an improved process for the preparation of [[2(S)-[[4(R)-(3-hydroxyphenyl)-3(R),4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]amino]acetic acid dihydrate, represented by the following structural formula (I).
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: October 9, 2018
    Assignee: MSN Laboratories Private Limited
    Inventors: Srinivasan Thirumalai Rajan, Sajja Eswaraiah, Komati Satyanarayana
  • Methods and compositions for treatment of demyelinating diseases
    Patent number: 10085955
    Abstract: Disclosed herein are new oral pharmaceutical compositions of SAMDC inhibitors, polyamine analogs, and polyamine biosynthesis inhibitors, and their application for the treatment of conditions including demyelinating diseases, autoimmune disorders affecting the nervous system, and other neurodegenerative conditions.
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: October 2, 2018
    Assignee: Pathologica LLC
    Inventors: Jeremy Blitzer, John McKearn
  • Dosage of dasotraline and method for treatment of ADHD
    Patent number: 10076503
    Abstract: Dosage forms and treatment regimens employing dasotraline for treating Attention Deficit Hyperactivity Disorder (ADHD) are disclosed. The compositions described herein exhibit no abuse potential.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: September 18, 2018
    Assignee: SUNOVION PHARMACEUTICALS INC.
    Inventors: Antony D. Loebel, Kenneth S. Koblan
  • Specific mTOR inhibitors in the treatment of X-linked adrenoleukodystrophy
    Patent number: 10071063
    Abstract: The invention relates to novel uses of specific mTOR inhibitors as a medicament, in particular for the treatment of X-linked adrenoleukodystrophy (X-ALD). The invention also relates to a method for identifying a compound potentially useful for the treatment and/or prevention of X-ALD.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: September 11, 2018
    Assignees: FUNDACION DE LA COMUNIDAD VALENCIANA ENTRO DE INVESTIGACION PRINCIPE FELIPE, INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE (IDIBELL), CENTRO DE INVESTIGACION BIOMEDICA EN RED (CIBER), INSTITUCIO CATALANA DE RECERCA TESTUDIS AVANCATS
    Inventors: Aurora Pujol Onofre, Erwin Knecht Roberto
  • Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto
    Patent number: 10052332
    Abstract: The disclosure relates to Prostaglandin receptor EP2 antagonists, derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing conditions and diseases in which EP2 receptor activation has a physiological role, such as but not limited to, brain injury, inflammatory diseases, neuroinflamation after a seizure, pain, endometriosis, cancer, rheumatoid arthritis, skin inflammation, vascular inflammation, colitis, and neurological disorders by administering a pharmaceutical composition comprising a compound disclosed herein to a subject in need thereof.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: August 21, 2018
    Assignee: Emory University
    Inventors: Thota Ganesh, Jianxiong Jiang, Ray J. Dingledine
  • Compositions and methods employing FtsZ as a target for Albendazole sulfone
    Patent number: 10028936
    Abstract: Compositions and Methods are described in which Albendazole sulfone binds to Wolbachia FtsZ providing anti filarial activity.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: July 24, 2018
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Laura Serbus, Fredric Landmann, Catharina Lindley, Pamela White, William Sullivan